Core Viewpoint - Zhonghui Biotech-B (02627) has seen its stock price increase over 20%, reaching a new high of 54 HKD, which is three times its IPO price of 12.9 HKD [1] Group 1: Stock Performance - As of the latest update, the stock is up 22.65%, trading at 53.6 HKD with a transaction volume of 43.85 million HKD [1] - The company's total market capitalization has surpassed 21 billion HKD [1] Group 2: Product Development - Zhonghui Biotech announced that its quadrivalent influenza virus subunit vaccine, branded as Huiru Kangs, has been included in the preliminary review list of innovative drugs for national commercial health insurance [1] - The vaccine received New Drug Application (NDA) approval from the National Medical Products Administration of China in May 2023, and it is intended for individuals aged three and above [1] - This vaccine is the first and only quadrivalent influenza virus subunit vaccine approved in China until July 21, 2025 [1]
中慧生物-B再涨超20% 四价流感病毒亚单位疫苗入选商保创新药目录初审名单